Results 1 to 10 of about 507,096 (126)

A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls. [PDF]

PLoS ONE, 2013
The current generation of Human Papillomavirus (HPV) vaccines, Cervarix® and Gardasil®, exhibit a high degree of efficacy in clinical trials against the two high-risk (HR) genotypes represented in the vaccines (HPV16 and HPV18).
Eve Draper, Sara L Bissett, Rebecca Howell-Jones, Pauline Waight, Kate Soldan, Mark Jit, Nicholas Andrews, Elizabeth Miller, Simon Beddows   +8 more
doaj   +4 more sources

Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine. [PDF]

PLoS ONE, 2015
BackgroundHuman papillomavirus (HPV) vaccines confer protection against the oncogenic genotypes HPV16 and HPV18 through the generation of type-specific neutralizing antibodies raised against virus-like particles (VLP) representing these genotypes.
Anna Godi, Sara L Bissett, Elizabeth Miller, Simon Beddows   +3 more
doaj   +3 more sources

Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination [PDF]

npj Vaccines, 2023
Gardasil® (Merck) and Cervarix® (GlaxoSmithKline) both provide protection against infection with Human Papillomavirus 16 (HPV16) and Human Papillomavirus 18 (HPV18), that account for around 70% of cervical cancers. Both vaccines have been shown to induce
Vicky Roy, Wonyeong Jung, Caitlyn Linde, Emily Coates, Julie Ledgerwood, Pamela Costner, Galina Yamshchikov, Hendrik Streeck, Boris Juelg, Douglas A. Lauffenburger, Galit Alter   +10 more
doaj   +2 more sources

A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX®) in female school students in Thailand. [PDF]

PLoS ONE, 2022
Human papillomavirus (HPV) is a common infection principally spread through sexual activity. Most HPV infections are asymptomatic and resolve spontaneously. However, persistent infection may progress to cervical cancer.
Suchada Jiamsiri, Chulwoo Rhee, Hyeon Seon Ahn, Nimesh Poudyal, Hyeong-Won Seo, Worrawan Klinsupa, Pornjarim Nilyanimit, Nakorn Premsri, Chawetsan Namwat, Sompong Vonpunsawad, Yun Chon, Sunju Park, Deok-Ryun Kim, Elizabeth R Unger, Lauri Markowitz, Yong Poovorawan, Supachai Rerks-Ngarm, Jean Louis Excler, Julia Lynch   +18 more
doaj   +2 more sources

Real-world safety of HPV vaccines over 18 y: A comprehensive analysis of U.S. VAERS reports [PDF]

Human Vaccines & Immunotherapeutics
Human papillomavirus (HPV) vaccination is central to preventing cervical and other HPV-associated cancers. Although clinical trials have established favorable safety profiles, long-term, brand-specific real-world data remain limited. We evaluated adverse
Yonglong Su, Yirong Huang, Jinbao Wei, Xinjin Wang, Yanyan Zhou, Xiaohong Wu, Honghong Fu   +6 more
doaj   +2 more sources

AS04 drives superior cross-protective antibody response by increased NOTCH signaling of dendritic cells and proliferation of memory B cells [PDF]

Frontiers in Immunology
IntroductionThe Gardasil-4® vaccine targets HPV types 6, 11, 16 and 18 and is formulated with amorphous alum. Cervarix® targets HPV types 16 and 18 using AS04 (Al(OH)3 + TLR4 agonist MPL) to enhance immune response.
Valentino D’Onofrio, Ana Carolina Santana, Ana Carolina Santana, Marthe Pauwels, Marthe Pauwels, Gwenn Waerlop, Anthony Willems, Fien De Boever, Martin Müller, Peter Sehr, Tim Waterboer, Isabel Leroux-Roels, Ashish A. Sharma, Ashish A. Sharma, Rafick Pierre Sékaly, Rafick Pierre Sékaly, Geert Leroux-Roels   +16 more
doaj   +2 more sources

Memory B-cells elicited by different HPV vaccine regimens in the DoRIS randomised controlled trial [PDF]

npj Vaccines
Prophylactic human papillomavirus vaccines such as Cervarix® and Gardasil®9 induce robust and sustained antibody responses over time. One driver of such responses is memory B-cells (MBCs), primed during initial HPV-vaccine exposure.
Rebecca Wiggins, Kathy J. Baisley, Jackton Indangasi, John Changalucha, Helen Ashwin, Najmeeyah Brown, Hilary S. Whitworth, David Joakim, Philippe Mayaud, Ramadhan Hashim, Caroline Maxwell, Paul Mutani, Beatrice Kamala, Brett Lowe, Ligia Pinto, Troy Kemp, Silvia deSanjosé, Saidi Kapiga, Richard J. Hayes, Deborah Watson-Jones, Charles J. Lacey   +20 more
doaj   +2 more sources

Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda. [PDF]

PLoS ONE, 2016
The objective of this study was to determine the prevalence and some predictors for vaccine and non-vaccine types of HPV infections among bivalent HPV vaccinated and non-vaccinated young women in Uganda.
Edward Kumakech, Vanja Berggren, Henry Wabinga, Gabriella Lillsunde-Larsson, Gisela Helenius, Malin Kaliff, Mats Karlsson, Samuel Kirimunda, Caroline Musubika, Sören Andersson   +9 more
doaj   +2 more sources

Chlamydia trachomatis Infection and Its Association with Human Papillomavirus Among Adolescent Girls and Young Women of Eastern Cape, South Africa [PDF]

Epidemiologia
Background/Objectives: Adolescent girls and young women (AGYW) have a high burden of sexually transmitted infections (STIs). This study examined the prevalence of Chlamydia trachomatis, its association with human papillomavirus (HPV), and other ...
Olufunmilayo O. Akapo, Zizipho Z. A. Mbulawa   +1 more
doaj   +2 more sources

Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded [PDF]

Infectious Agents and Cancer
Several high-risk types of human papillomaviruses (HPVs) are associated with cervical cancer and other malignancies. Despite the tremendous success of marketed prophylactic HPV vaccines for the past 18 years, cervical cancer remains a significant global ...
Sogand Amiri, Shiva Rasekh, Seyed Mohammad Iman Moezzi, Nadia Seifi, Seyed Amirreza Fatemi, Shirin Fathi, Ashkan Bagheri, Manica Negahdaripour   +7 more
doaj   +2 more sources